Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells.

Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Oikawa S, Murata M.

Genes Environ. 2017 Jan 1;38:26. doi: 10.1186/s41021-016-0055-7. Review.

2.

Design, Construction and Evaluation of 1a/JFH1 HCV Chimera by Replacing the Intergenotypic Variable Region.

Ghasemi F, Ghayour-Mobarhan M, Pasdar A, Pourianfar H, Reza Aghasadeghi M, Gouklani H, Meshkat Z.

Hepat Mon. 2016 Aug 7;16(10):e38261.

3.

HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway.

Zhang Q, Wang Y, Zhai N, Song H, Li H, Yang Y, Li T, Guo X, Chi B, Niu J, Crispe IN, Su L, Tu Z.

Sci Rep. 2016 Oct 27;6:36160. doi: 10.1038/srep36160.

4.

In vitro model of production of antibodies; a new approach to reveal the presence of key bacteria in polymicrobial environments.

Wu C, Nakka S, Mansouri S, Bengtsson T, Nayeri T, Nayeri F.

BMC Microbiol. 2016 Sep 9;16:209. doi: 10.1186/s12866-016-0821-5.

5.

Effect of Antiviral Therapy on Serum Activity of Angiotensin Converting Enzyme in Patients with Chronic Hepatitis C.

Husic-Selimovic A, Sofic A, Huskic J, Bulja D.

Med Arch. 2016 Apr;70(2):92-6. doi: 10.5455/medarh.2016.70.92-96.

6.

Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.

Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T.

PLoS One. 2016 Mar 22;11(3):e0151828. doi: 10.1371/journal.pone.0151828.

7.

Single-center study on transplantation of livers donated after cardiac death: A report of 6 cases.

Sun XY, Dong JH, Qin KE, Lan LG, Li HB, Huang Y, Cao S, Li ZJ, Dai LJ.

Exp Ther Med. 2016 Mar;11(3):988-992.

8.

A Novel Structurally Stable Multiepitope Protein for Detection of HCV.

Galdino AS, Santos JC, Souza MQ, Nóbrega YK, Xavier MA, Felipe MS, Freitas SM, Torres FA.

Hepat Res Treat. 2016;2016:6592143. doi: 10.1155/2016/6592143.

9.

The Association of Chronic Hepatitis C with Respiratory Microbiota Disturbance on the Basis of Decreased Haemophilus Spp. Colonization.

Kosikowska U, Biernasiuk A, Korona-Głowniak I, Kiciak S, Tomasiewicz K, Malm A.

Med Sci Monit. 2016 Feb 25;22:625-32.

10.

MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations.

Louten J, Beach M, Palermino K, Weeks M, Holenstein G.

Biomark Insights. 2016 Jan 18;10(Suppl 4):25-52. doi: 10.4137/BMI.S29512. Review.

11.
12.

Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C.

Enomoto H, Nishiguchi S.

World J Hepatol. 2015 Nov 18;7(26):2681-7. doi: 10.4254/wjh.v7.i26.2681. Review.

13.

Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.

Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R.

Acta Pharm Sin B. 2015 May;5(3):194-200. doi: 10.1016/j.apsb.2015.02.003.

14.

Progress in the development of vaccines for hepatitis C virus infection.

Ghasemi F, Rostami S, Meshkat Z.

World J Gastroenterol. 2015 Nov 14;21(42):11984-2002. doi: 10.3748/wjg.v21.i42.11984. Review.

15.

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-Klosińska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W.

Medicine (Baltimore). 2015 Sep;94(38):e1411. doi: 10.1097/MD.0000000000001411.

16.

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.

Nakamoto S, Imazeki F, Arai M, Yasui S, Nakamura M, Haga Y, Sasaki R, Kanda T, Shirasawa H, Yokosuka O.

Int J Mol Sci. 2015 Sep 7;16(9):21177-90. doi: 10.3390/ijms160921177.

17.

Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.

Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T.

PLoS One. 2015 Jul 27;10(7):e0133515. doi: 10.1371/journal.pone.0133515.

18.

NGF and P75NTR gene expression is associated with the hepatic fibrosis stage due to viral and non-viral causes.

Amoras Eda S, Gomes ST, Freitas FB, Santana BB, Ishak G, de Araújo MT, Demachki S, da Silva Conde SR, de Oliveira Guimarães Ishak M, Ishak R, Vallinoto AC.

PLoS One. 2015 Mar 27;10(3):e0121754. doi: 10.1371/journal.pone.0121754.

19.

Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection.

Maggio R, Viscomi C, Andreozzi P, D'Ettorre G, Viscogliosi G, Barbaro B, Gori M, Vullo V, Balsano C.

PLoS One. 2014 Dec 22;9(12):e112346. doi: 10.1371/journal.pone.0112346.

20.

Comparative salivary proteome of hepatitis B- and C-infected patients.

Gonçalves Lda R, Campanhon IB, Domingues RR, Paes Leme AF, Soares da Silva MR.

PLoS One. 2014 Nov 25;9(11):e113683. doi: 10.1371/journal.pone.0113683.

Items per page

Supplemental Content

Support Center